B-Cell Proliferation of Uncertain Malignant Potential

B-Cell Proliferation of Uncertain Malignant Potential — Trials · CancerIndex

Clinical trials

Registered studies

83 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	terminated	Phase 2	20	University of NebraskaOTHER	1	Sep 6, 2023	clinicaltrials
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	terminated	Phase 1 / Phase 2	20	Northwestern UniversityOTHER	1	Sep 1, 2021	clinicaltrials
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	terminated	Phase 2	3	Fred Hutchinson Cancer CenterOTHER	1	Jul 27, 2017	clinicaltrials
NCT00112723

Data updated 23 days agoSource updated Sep 6, 2023source: clinicaltrials